Late-stage COPD candidate aclidinium could transform the newly listed Spanish firm. The company's challenge is to monetize the fruits of its primary-care-focused R&D while pursuing a specialist expansion strategy.
Continue reading "Almirall: Adapting Primary-Care-focused R&D to a Specialist World" »
